Semaglutide and tirzepatide are the two prescription medications people most often ask about when they start looking into GLP-1 weight loss treatment. They're frequently mentioned in the same breath, and they do share a lot. But they aren't interchangeable, and the differences matter when a clinician is deciding which one, if either, fits a particular person.
This guide explains what each one is, how they work, how they differ, and what goes into choosing between them. It is not a recommendation. That decision belongs to a licensed clinician who has reviewed your health history.
What semaglutide is
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone the gut releases after eating. By activating GLP-1 receptors, semaglutide slows how quickly the stomach empties, supports the body's regulation of blood sugar, and acts on the appetite centers of the brain.
Semaglutide is the active ingredient in the FDA-approved brand-name medications Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management), both made by Novo Nordisk, and in the oral tablet Rybelsus. It is also available as a compounded medication, prepared by licensed compounding pharmacies, which is what Virgo-Meds programs use. Compounded medications are not FDA approved.
What tirzepatide is
Tirzepatide is a newer medication with a dual mechanism. It activates GLP-1 receptors, like semaglutide, and it also activates GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is a second gut hormone involved in insulin release and fat metabolism. Because tirzepatide acts on both pathways, it's often described as a "dual agonist" or "dual-action" medication.
Tirzepatide is the active ingredient in the FDA-approved brand-name medications Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management), both made by Eli Lilly. Like semaglutide, it is also available in compounded form. Compounded tirzepatide is not FDA approved.
Semaglutide vs. tirzepatide: the key differences
Mechanism
This is the fundamental difference. Semaglutide works on one hormone pathway (GLP-1). Tirzepatide works on two (GLP-1 and GIP). Whether the second pathway makes a meaningful difference for a given person is something only a clinician can judge, and it depends on their health history, how they've responded to medications in the past, and what they're trying to achieve.
How they're taken
Both are most commonly given as a once-weekly injection under the skin, usually in the abdomen, thigh or upper arm. Semaglutide is also available as a daily oral tablet; at Virgo-Meds that's a compounded dissolvable tablet for people who would rather avoid injections. Tirzepatide is currently injection only.
Dosing
Both medications are started at a low dose and increased gradually over several weeks or months. This is deliberate: it gives the body time to adjust and tends to reduce side effects. The specific starting dose, how quickly the dose increases, and where it settles are all set by the prescribing clinician and adjusted based on how the patient responds.
Research
Both molecules have been studied extensively in clinical trials of their FDA-approved, brand-name versions, including head-to-head comparisons. Those studies are a major reason clinicians have confidence in how these medications work. It's important to understand, though, that compounded versions of semaglutide and tirzepatide have not been studied in the same way. A clinician weighs the published evidence alongside each patient's individual situation.
Side effects
The side-effect profiles overlap substantially because both medications slow stomach emptying. The most commonly reported effects are gastrointestinal: nausea, constipation, diarrhea, vomiting and reduced appetite, often most noticeable when starting or increasing a dose. Both carry a boxed warning related to thyroid C-cell tumors observed in animal studies, and neither should be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. Both have been associated with more serious risks including pancreatitis and gallbladder problems. Full safety information for the compounded medications used in Virgo-Meds programs is available on our medication safety page.
Cost
Pricing differs between the two and depends on the program. Virgo-Meds plans include the clinician visits, lab work, medication, delivery and care team in one monthly price, with no insurance required. Your clinician's recommendation comes first; the price for that program is shown in full before anything is paid.
How a clinician chooses between them
Patients sometimes arrive with a preference, often based on something they've read. That's fine to bring to the conversation, but it isn't how the decision gets made. A licensed clinician typically considers:
- Full medical history, including thyroid, pancreatic, gallbladder and kidney history
- Current medications and potential interactions
- Prior experience with GLP-1 medications, if any, and how they were tolerated
- Whether injection or oral administration is a better fit for the person's life
- Whether a lower-dose or more gradual approach makes sense
- Whether GLP-1 treatment is appropriate at all
That last point matters. Not everyone qualifies, and a clinician who reviews a health history and decides treatment isn't appropriate is doing exactly what they're supposed to do.
The programs available through Virgo-Meds
Virgo-Meds offers four clinician-guided GLP-1 programs: compounded semaglutide by weekly injection, compounded tirzepatide by weekly injection, a once-daily compounded oral semaglutide tablet, and a lower-dose semaglutide program for a more gradual approach. All are prescribed online by U.S.-licensed clinicians after a review of your health history, and shipped from licensed U.S. pharmacies. You can compare them on the weight loss programs page, or read about how the process works.
Frequently asked questions
Is tirzepatide better than semaglutide?
Neither is universally "better." They work differently, and the right choice depends on the individual. A licensed clinician makes that call after reviewing your health history.
Can I switch from semaglutide to tirzepatide, or the other way around?
Switching between GLP-1 medications is a clinical decision. It is never appropriate to take both at the same time. If you're currently on one and considering a change, raise it with your clinician.
Is there a tirzepatide pill?
Not at this time. Tirzepatide is given by injection. Semaglutide is available in oral form, including a compounded dissolvable tablet through Virgo-Meds.
Are compounded semaglutide and tirzepatide the same as the brand-name versions?
They contain the same active ingredient but are prepared by compounding pharmacies rather than the original manufacturer, and they are not FDA approved. You can read more in our guide to what compounded semaglutide is.
Start your free assessment · Takes about 2 minutes · 100% private · No commitment
This article is for general information only and is not medical advice. Prescription medications are available only if a licensed clinician determines they are medically appropriate, and a clinician may decline to prescribe. Compounded medications are not FDA approved; the FDA does not evaluate compounded products for safety, effectiveness or quality. Results are not guaranteed and vary by individual. Ozempic, Wegovy and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Virgo-Meds is not affiliated with either company.
